The downgrade from Outperform to Neutral by Evercore ISI Group analyst Gavin Clark-Gartner indicates a less optimistic outlook for Sarepta Therapeutics. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating and price target.